The significance of enzyme immunoassay for the assessment of hepatitis B virus core-related antigen following liver transplantation

Internal Medicine

Volumn 48, Issue 18, 2009, Pages 1577-1583

  Fujimoto, Masumi ^a   Ichikawa, Tatsuki ^a   Nakao, Kazuhiko ^a   Miyaaki, Hisamitsu ^a   Shibata, Hidetaka ^a   Eguchi, Susumu ^a   Takatsuki, Mitsuhisa ^a   Nagaoka, Shinya ^b   Yatsuhashi, Hiroshi ^b   Kanematsu, Takashi ^a   Eguchi, Katsumi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Hepatitis B virus; Hepatitis B virus core related antigen; Liver transplantation

Indexed keywords

ADEFOVIR DIPIVOXIL; HEPATITIS B CORE ANTIGEN; LAMIVUDINE;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ENZYME IMMUNOASSAY; FEASIBILITY STUDY; FEMALE; HEPATITIS B; HUMAN; LIVER TRANSPLANTATION; LIVING DONOR; MALE; POSTOPERATIVE PERIOD; PROPHYLAXIS; VIRUS REPLICATION;

ADENINE; ADULT; AGED; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOENZYME TECHNIQUES; LAMIVUDINE; LIVER TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; TIME FACTORS; VIRUS REPLICATION;

EID: 70349501767     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.48.2000     Document Type: Article

References (34)

1. Tung BY, Kowdley KV. Hepatitis B and liver transplantation. Clin Infect Dis 41: 1461-1466, 2005.
2. Han SHB, Ofman J, Holt C, et al. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transplantation 6: 741-748, 2000.
3. Marzano A, Salizzoni M, Debernardi-Venon W, Smedile A, Franchello A, Ciancio A. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 34: 903-910, 2001.
4. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against post transplantation hepatitis B. Liver Transpl 6: 429-433, 2000.
5. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B immunoglobulin prophylaxis. Liver Transpl 12: 253-258, 2006.
6. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 28: 585-589, 1998.
7. Seefer D, Berg T. Prevention of hepatitis B recurrence after liver transplantation. Transplantation 80: S120-S124, 2005.
8. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver transpl 11: 402-409, 2005.
9. Madhu S, Dicaire A, Wakil AE, Luscombe C, Sacks SL. Quantitation of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) in the liver of HBV-infected patients by Light Cycler real-time PCR. J Virol Methods 118: 159-167, 2004.
10. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology 128: 1890-1897, 2005.
11. Kimura T, Rokuhara A, Matsumoto A, et al. New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA. J Clin Microbiol 41: 1901-1906, 2003.
12. Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 40: 439-445, 2002.
13. Kimura T, Ohno N, Terada N, et al. Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain. J Biol Chem 280: 21713-21719, 2005.
14. Rokuhara A, Sun X, Tanaka E, et al. Hepatitis B virus core and core-related antigen quantitation in Chinese patients with chronic genotype B and C hepatitis B virus infection. J Gastroenterol Hepatol 20: 1726-1730, 2005.
15. Shinkai N, Tanaka Y, Orito E, et al. Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection. Hepatol Res 36: 272-276, 2006.
16. Tanaka E, Matsumoto A, Suzuki F, et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int 26: 90-96, 2006.
17. Suzuki F, Miyakoshi H, Kobayashi M, Kumada H. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol 81: 27-33, 2009.
18. Rokuhara A, Tanaka E, Matsumoto A, et al. Clinical evaluation of a new enzyme immunoassay for hepatitis B virus core-related antigen; a marker distinct from viral DNA for monitoring lamivudine treatment. J Viral Hepat 10: 324-330, 2003.
19. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126: 1750-1758, 2004.
20. Tanaka Y, Takagi K, Hiramatsu K, et al. Fundamental and clinical evaluation of hepatitis B virus core-related antigen assay by LUMIPULSE f. Rinsho Byori 54: 692-698, 2006 (in Japanese).
21. Misawa N, Matsumoto A, Tanaka E, et al. Patients with and without loss of hepatitis B virus DNA after hepatitis B e antigen seroconversion have different virological characteristics. J Med Virol 78: 68-73, 2006.
22. Rokuhara A, Matsumoto A, Tanaka E, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol 41: 785-790, 2006.
23. Yuen MF, Wong K, Sum SS, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc)DNA of chronic hepatitis B infection. Am J Gastroenterol 100: 1099-1103, 2005.
24. Hatakeyama T, Noguchi C, Hiraga N, et al. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine. Hepatology 45: 1179-1186, 2007.
25. Deguchi M, Yamashita N, Kagita M, et al. Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay. J Virol Methods 115: 217-222, 2004.
26. Wai CT, Prabhakaran K, Wee A, et al. Adefovir dipivoxil as the rescue therapy for lamivudine-resistant hepatitis B post liver transplant. Transplantation Proceedings 36: 2313-2314, 2004.
27. Schiff ER, Lai XL, Hadziyannis S, et al. Adefovir dipivoxil therapy for lamivudine resistant hepatitis B in pre- and post-liver transplantation patients. Hepatology 38: 1419-1927, 2003.
28. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 44: 703-712, 2006.
29. Charlton M. Liver biopsy, viral kinetics, and the impact of viremia on severity of hepatitis C virus recurrence. Liver Transpl 9: S58-S 62, 2003.
30. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 10: S74-S85, 2004.
31. Bock CT, Tillmann HL, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 122: 264-273, 2002.
32. Mazet-Wagner AA, Baclet MC, Loustaud-Ratti V, Denis F, Alain S. Real-time PCR quantitation of hepatitis B virus total DNA and covalently closed circular DNA in peripheral blood mononuclear cells from hepatitis B virus-infected patients. J Virol Methods 138: 70-79, 2006.
33. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histrogic recurrence of hepatitis C after liver transplantation. Hepatology 32: 1125-1130, 2000.
34. Ballardini G, De Raffele E, Groff P, et al. Timing of reinfection and mechanisms of hepatocellular damage in transplanted hepatitis C virus-reinfected liver. Liver Transpl 8: 10-20, 2002.